SoftBank Vision Fund led a series C round for the cancer therapy developer that was also backed by GV and Alexandria Venture Investments.

Relay Therapeutics, a US-based developer of protein-focused medicines, closed a $400m series C round led by SoftBank Vision Fund, the $98.6bn fund run by telecommunications firm Softbank, yesterday.

GV, an early-stage investment vehicle for internet technology group Alphabet, also took part in the round, as did Alexandria Venture Investments, the strategic investment division of life sciences real estate investment trust Alexandria Real Estate Equities.

DE Shaw, Casdin Capital, BVF Partners, EcoR1 Capital, Foresite Capital, Perceptive Advisors and Tavistock Group also…